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Abstract Engagement of the interleukin-1 (IL1) and Toll re-
ceptors, which are part of the innate immune system, facilitates
activation of the transcription factors NF-UB, Elk-1 and AP-1.
Pellino1 and Pellino2 have recently been shown to be intermedi-
ates in the pathway leading to activation of NF-UB. Here we
demonstrate for the ¢rst time that human Pellino2 interacts with
TRAF6 (tumor necrosis factor receptor associated factor 6) and
that both Pellino1 and Pellino2 also interact with TAK1 (trans-
forming growth factor-L activated kinase 1). We also show that
Pellino2, but not Pellino1, can activate the mitogen activated
protein kinase pathway leading to activation of AP-1 and Elk-1.
These observations suggest a role for the Pellino proteins in the
IL1/Toll signaling cascades as sca¡old proteins that may regu-
late signaling branch-points.
/ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The innate immune system involves the local recognition of
foreign agents such as bacterial lipopolysaccharide, peptido-
glycan, DNA and viral double stranded RNA. These agents
are speci¢cally recognized by the Toll-like receptor family
[1,2]. Engagement of the Toll-receptors triggers antimicrobial
responses and the production of cytokines, including interleu-
kin-1 (IL1). This in turn initiates the systemic acute phase
response encompassing physiological changes that include fe-
ver, increased vascular permeability, hypotension, increased
levels of circulating nitric oxide, in¢ltration of in£ammatory
cells and stimulation of the hypothalamic^pituitary^adrenal
axis and corticosterone synthesis [3].
The Toll and IL1 receptors activate common intracellular
signaling cascades [4]. A central consequence of signaling
from the Toll and IL1 receptors is the activation of NF-UB,
Elk-1, CHOP and AP-1 (homo- or hetero-dimers of cFos,
cJun and/or ATF). These factors mediate the increased tran-
scription of numerous genes and hence the increased synthesis
of a range of proteins, many of which are involved in immu-
nological responses. These include the kappa light chain of
immunoglobulin, complement components, adhesion mole-
cules and the major acute phase reactants, C-reactive protein
and serum amyloid A protein [5].
The best described signaling cascade initiated by IL1 in-
volves a trimeric protein complex of IL1, the IL1 receptor
and IL1 receptor accessory protein [4]. This complex recruits
the adapter protein MyD88 via the intracellular domains of
the receptor and the accessory protein, an event that facili-
tates the subsequent recruitment of IL1 receptor associated
kinase 1 (IRAK1) and IRAK4. The signaling cascade pro-
gresses through several downstream adapter proteins and ki-
nases, including tumor necrosis factor receptor associated fac-
tor 6 (TRAF6), TRAF6 binding protein, two transforming
growth factor-L activated kinase 1 (TAK1) binding proteins,
and TAK1. TAK1 itself in turn activates the IUB kinase com-
plex which contains the two IUB kinases IKK-K and IKK-L,
as well as NF-UB bound to IUB [4]. IUB becomes phosphor-
ylated and is degraded by the ubiquitin^proteasome pathway,
after which NF-UB can translocate to the nucleus where it
activates transcription by binding to speci¢c sites in the pro-
moters of numerous genes.
The signaling pathways which lead to the activation of AP-
1, Elk-1 and CHOP are less well characterized. While some
studies have suggested that these sub-pathways branch from
the NF-UB activating pathway at, or after, TAK1 ([6] and
references therein), others have suggested that they diverge
at IRAK1 [7]. ECSIT (evolutionarily conserved signaling in-
termediate in Toll, [8]) pathways, mitogen activated protein
(MAP) kinase/ERK kinase kinase 1 (MEKK1) and cJun
N-terminal kinase (JNK) are sequentially engaged upstream
activators of AP-1 [9], whereas Ras and p38 are involved in
the activation of CHOP [10].
Many of the components of the IL1 signaling cascade are
evolutionarily conserved across phyla. Investigations of the
Drosophila signaling pathway have led to the identi¢cation
of a novel protein, termed Pellino, that binds to Pelle (the
homologue of IRAK) [11]. Two homologues of Pellino have
been identi¢ed in mouse and humans [12,13]. It has recently
been shown that mammalian Pellino1 and Pellino2 are re-
quired for activation of NF-UB [14,15], but the exact functions
of these proteins remain poorly understood.
2. Materials and methods
2.1. Cloning and expression vectors
MyD88 and TRAF6 constructs are described elsewhere [16,17].
Pellino1 and Pellino2 cDNAs (GenBank accession nos. AF302505
and AF302502) were ampli¢ed by PCR and cloned into the mamma-
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lian expression vector p3XFLAG-CMV-14 (Sigma, St. Louis, MO,
USA). The coding sequence of TAK1 (alternative splice variant A,
GenBank accession no. AB009356) was cloned into pcDNA4/HisMax
(Invitrogen, Carlsbad, CA, USA). The integrity of all constructs was
con¢rmed by sequencing.
2.2. Cell line and cultures
Human embryonic kidney cells (293 cells) were obtained from the
American Type Culture Collection and maintained in Dulbecco’s
modi¢ed Eagle’s medium supplemented with 10% fetal calf serum
and 50 Wg ml31 gentamicin (GibcoBRL, Grand Island, NY, USA).
Cells were transfected as described elsewhere [17]. Cells were treated
with 10 ng ml31 IL1K (National Cancer Institute, Frederick, MD,
USA) for 6 h. All experiments were performed at least three times
with similar outcomes.
2.3. Western blotting and immunoprecipitation
Total proteins were extracted as described elsewhere [17]. Flag
tagged proteins (100 Wl) were immunoprecipitated in Anti-Flag0
HS, M2 monoclonal antibody coated 96-well plates (Sigma) at 4 ‡C
for 4 h. Wells were rinsed three times (5^20 s) and washed three times
(5^10 min) in Dulbecco’s PBS (phosphate-bu¡ered saline) with mag-
nesium and calcium, 0.1% NP-40. Proteins bound to the wells were
eluted in 100 Wl 65% lysis bu¡er, 100 mM dithiothreitol (DTT), 2 M
urea, 0.85% sodium dodecyl sulfate (SDS), 2.5% glycerol for 10 min.
Proteins were separated in NuPAGE 4^12% Bis^Tris gels (SDS^poly-
acrylamide gel electrophoresis (PAGE), Invitrogen) and transferred to
Hybond ECL nitrocellulose membranes (Amersham Pharmacia Bio-
tech, Piscataway, NJ, USA). Immunodetection was performed as de-
scribed elsewhere [17].
2.4. Reporter assays
The renilla^luciferase reporter construct (pRL-null) was obtained
from Promega. The PathDetect cJun, Elk-1 and CHOP trans-Report-
ing Systems were obtained from Stratagene (La Jolla, CA, USA) and
used according to the manufacturer’s instructions. In brief, 50 ng of
the luciferase reporter plasmid pFR-Luc, in which expression of lu-
ciferase is driven by a GAL4 inducible promoter, was co-transfected
into 2.5U105 cells with 5 ng pFA2-cJun (or pFA2-Elk1/pFA-CHOP)
(encoding the trans-activating fusion protein GAL4-cJun (or GAL4-
Elk1/GAL4-CHOP)), 5 ng pRL-null and variable amounts of Pellino
expression constructs. Control cells were transfected with pFC2-dbd
(encoding only the GAL4 DNA binding domain residues 1^147) in-
stead of pFA2-cJun/pFA2-Elk1/pFA-CHOP. For experiments in
which cells were transfected with varying amounts of expression vec-
tors the total DNA used in each transfection was held constant by co-
transfecting appropriate amounts of empty vector. For luciferase re-
porter assays luciferase and renilla^luciferase activities in cell lysates
were measured according to the manufacturer’s instructions (Dual-
Luciferase Reporter Assay System, Promega). Reporter assays were
performed in duplicate or triplicate.
2.5. Kinase assays
Total protein was extracted from cells and JNK immunoprecipi-
tated as described above using anti-JNK2 (FL, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and protein A^agarose (Invitrogen).
Washed immunoprecipitates were resuspended in kinase bu¡er
(20 mM Tris, pH 7.6, 1 mM DTT, 20 mM MgCl2, 20 mM L-glycer-
ophosphate, 1 mM EDTA, 1 mM Na3VO4, 50 mM NaF, 20 mM
p-nitrophenylphosphate, 10% protease inhibitor mixture and 5 WM
ATP) and separated into two aliquots. One aliquot was used for
quantitation of JNK protein immunoprecipitated using Western blot-
ting. The second aliquot was used for the JNK kinase assay. GST-
ATF2 (1 Wg, generous gift from Dr. Federico Coluccio Leskow) and
10 WCi of [Q-32P]ATP (Amersham Pharmacia Biotech) were added and
samples incubated at 37‡C for 30 min. Reactions were stopped by
addition of 100 mM DTT, 2 M urea, 0.85% SDS, 2.5% glycerol
and boiling for 5 min. Proteins were separated by SDS^PAGE and
visualized using autoradiography.
3. Results
3.1. Pellino1 and Pellino2 interact with TRAF6 and TAK1
Mammalian Pellino1 and Pellino2 have previously been
shown to interact with IRAK1 [14,15]. Pellino1 has also
been shown to interact with TRAF6 [14]. To determine
whether Pellino1 and/or Pellino2 could interact with signaling
factors in the IL1 pathway upstream and downstream of
IRAK1, Flag tagged Pellino1 and Pellino2 were co-expressed
with MyD88, TRAF6 or TAK1 in 293 cells. Flag tagged
Pellino proteins were immunoprecipitated and proteins co-
precipitating with the Pellino proteins analyzed using Western
blotting. MyD88, which is upstream of IRAK1, was not de-
tected after immunoprecipitation (not shown). In contrast,
both TRAF6 and TAK1, which are downstream of IRAK1,
were speci¢cally co-precipitated with both Pellino1 and Pelli-
no2 (Fig. 1) in samples derived from cells transfected with the
respective Pellino expression construct, but not in samples
derived from cells which had been transfected with empty
vector. This establishes that there are speci¢c direct interac-
tions between the Pellino proteins and both TRAF6 and
TAK1.
3.2. Pellino2 promotes activation of cJun and Elk-1
The capacity of Pellino1 and Pellino2 to promote activation
of the transcription factors cJun (one of the subunits of the
AP-1 dimer), Elk-1 and CHOP, which are end-point compo-
nents of IL1/Toll signaling sub-pathways distinct from that
leading to NF-UB activation, was tested. Over-expression of
increasing amounts of Pellino2 in the presence of the cJun and
Elk-1 PathDetect reporter systems resulted in concentration
dependent increases in luciferase activity (Fig. 2A). At the
highest levels of transfected Pellino2 cDNA cJun and Elk-1
driven luciferase activity was increased eleven- and seven-fold,
respectively. This strongly suggests that Pellino2 is involved in
the signaling sub-pathways that lead to activation of AP-1
and Elk-1. In contrast, over-expression of Pellino1 had no
such e¡ect (Fig. 2B). Over-expression of Pellino2 did not af-
fect the luciferase levels expressed using the CHOP PathDe-
tect reporter system or the pFC2-dbd control plasmid encod-
ing only the GAL4 DNA binding domain (Fig. 2A),
Fig. 1. Protein interactions with Pellino proteins. Cells were trans-
fected with empty expression vector (mock) or expression vectors en-
coding Flag tagged Pellino1 or Flag tagged Pellino2. Cells were ad-
ditionally transfected with an expression vector encoding TRAF6
(upper four panels) or TAK1 (lower four panels). Flag tagged pro-
teins were immunoprecipitated, and total lysates and immunopreci-
pitates analyzed by Western blotting. Equal volumes of total lysates
and eluted immunoprecipitated proteins were used. TRAF6, TAK1
and Pellino proteins were detected using anti-TRAF6 (H274, Santa
Cruz Biotechnology), anti-TAK1 (M579, Santa Cruz Biotechnology)
and anti-Flag (M2, Sigma), respectively.
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establishing that the e¡ects of Pellino2 in the cJun and Elk-1
reporter systems are speci¢c.
The above experiments were repeated in the presence of
IL1. This cytokine treatment did not a¡ect the degree of Pel-
lino2 mediated cJun or Elk-1 activation, nor the inability of
Pellino1 to mediate a similar e¡ect (not shown).
We further tested if Pellino1 could inhibit or enhance the
Pellino2 mediated cJun and Elk-1 activation. Cells were trans-
fected with either the cJun or Elk-1 reporter systems, 135 ng
Pellino2 expression construct and increasing amounts of Pel-
lino1 expression construct. Co-expression of Pellino1 with Pel-
lino2 did not a¡ect the degree of Pellino2 mediated reporter
activation under any of the test conditions (not shown).
3.3. Pellino2 activates JNK
Elk-1 and cJun are activated by phosphorylation. This
event can be mediated by JNK, which itself is activated by
phosphorylation. To examine whether Pellino1 and/or Pelli-
no2 can activate JNK we performed in vitro kinase assays
using ATP2, which is also activated by JNK, as a kinase
substrate (Fig. 3). Only Pellino2 could activate the kinase
activity of JNK, i.e. ATP2 was only phosphorylated in sam-
ples from cells over-expressing Pellino2. This observation is in
agreement with our data using the PathDetect reporter system
(Fig. 2), and establishes that Pellino2, but not Pellino1, acti-
vates the MAP kinase pathway.
4. Discussion
Pellino1 and Pellino2 have recently been shown to be in-
volved in the Toll/IL1 signaling cascades leading to activation
of NF-UB [14,15]. However the precise function of these pro-
teins still remains to be determined. While both proteins have
been shown to interact with IRAK1 [14,15], only Pellino1 has
previously been shown to interact with TRAF6 [14]. Here we
have demonstrated that Pellino2 also interacts with TRAF6.
The dual interaction of Pellino1 and Pellino2 with IRAK1
and TRAF6 strongly suggests a role for the Pellino proteins
in the IL1/Toll signaling cascade as either adapter or sca¡old
proteins. Given that it has been shown that IRAK1 can asso-
ciate directly with TRAF6 [17,18], the latter may be a more
accurate description. Several sca¡olding proteins have been
described for the MAP kinase signaling pathways (reviewed
in [19]). The role of such sca¡olding proteins is to assemble
multiple signaling factors into functional protein complexes.
Activated IRAK1 has previously been shown to be part of a
large multiprotein complex (600^800 kDa) [20]. Our novel
observation that both Pellino1 and Pellino2 also interact
with TAK1 supports a role for the Pellino proteins as scaf-
folding proteins and suggests that they may hold IRAK1,
TRAF6 and TAK1 together in an activated signaling-compe-
tent protein complex.
Protein interactions are often in a dynamic equilibrium.
When a signaling event, such as binding of IL1 to its receptor,
occurs the equilibrium may be shifted towards formation of
protein complexes due to changes such as altered conforma-
tion or phosphorylation status. The ability of Pellino2 to fa-
cilitate ‘spontaneous’ activation of the MAP kinase pathway
when over-expressed may be attributed to an induced assem-
bly of functional signaling complexes of IRAK1, TRAF6 and
TAK1. According to LeCha“telier’s principle, the increased
levels of Pellino2 would force the equilibrium towards com-
plex formation even in the absence of an extracellular signal-
ing event. Once functional signaling complexes are formed
these could initiate downstream signaling events such as acti-
vation of JNK.
The branch-point at which the Toll/IL1 signaling sub-path-
ways leading to activation of NF-UB, AP-1 and Elk-1 diverge
Fig. 2. Pellino2 activates cJun and Elk-1. Cells were co-transfected
with pFC-Luc and renilla^luciferase reporter constructs plus the ac-
tivator/GAL4 fusion expression plasmids pFA2-cJun, pFA2-Elk1 or
pFA-CHOP or the control plasmid pFC2-dbd. Cells were addition-
ally transfected with increasing amounts of Pellino2 (A) or Pellino1
(B) expression constructs. Luciferase values were standardized
against renilla^luciferase to adjust for variations in transfection e⁄-
ciencies. The standardized luciferase values are graphically repre-
sented as fold induction compared to the values of cells transfected
only with reporter constructs and empty vector (0 ng). Triplicate
samples were analyzed and standard deviations are shown with er-
ror bars.
Fig. 3. Pellino2 can activate JNK. Cells were transfected with empty
vector, Pellino1 or Pellino2 expression constructs. Cells were lysed
and the expression of Pellino proteins veri¢ed using Western blot-
ting with anti-Flag antibodies (upper panel). Washed JNK immuno-
precipitates were separated into two aliquots, one of which was
used to quantitate the amount of JNK immunoprecipitated (middle
panel) and the other of which was used for in vitro kinase phos-
phorylation of the kinase substrate ATF2 (lower panel).
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is a matter of debate. Although one study has shown that
di¡erent domains of IRAK1 are required for activation of
the di¡erent sub-pathways, suggesting that the pathways di-
verge at IRAK1 [7], other studies, using dominant negative
mutants of TAK1, have suggested that they diverge at, or
after, TAK1 ([6] and references therein). These apparently
contradictory results may be reconciled if, rather than consid-
ering the signaling pathway to be strictly linear, a third di-
mension involving sca¡olding proteins is introduced. Upon
activation IRAK1 interacts with TRAF6 and may also inter-
act with several di¡erent sca¡olding proteins, including Pelli-
no1 and Pellino2. Di¡erent domains of IRAK1 may be in-
volved in the interactions with di¡erent sca¡olding proteins.
TAK1 is then recruited into the protein complex. Depending
on which sca¡olding protein IRAK1/TRAF6/TAK1 is asso-
ciated with, the protein complex will be directed towards dif-
ferent sub-pathways. Given the previously reported involve-
ment of Pellino1 and Pellino2 in NF-UB activation [14,15] and
our observations that Pellino2, but not Pellino1, can activate
the MAP kinase pathway, Pellino1 may act as a sca¡olding
protein that directs and commits the signaling complex exclu-
sively towards NF-UB activation, whereas Pellino2 may per-
mit the complex to facilitate the engagement of both sub-
pathways.
Here we have established that Pellino2, as well as Pellino1,
interacts with TRAF6. We have also shown for the ¢rst time,
that both Pellino proteins interact with TAK1. Furthermore,
our results suggest that the Pellino proteins act as sca¡olding
proteins that di¡erentially support the signaling sub-pathways
leading to Elk-1, AP-1 and NF-UB activation, since Pellino2,
but not Pellino1, can activate cJun and Elk-1. This under-
scores the potential importance of Pellino1 and Pellino2 as
critical regulators of speci¢city in the IL1/Toll signaling cas-
cades.
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